Candriam S.C.A. Aprea Therapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 20, 2021	SELL	$4.05 - $5.5 $1.47 Million - $1.99 Million	-362,319 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$4.73 - $8.15 $127 - $220	-27 Reduced 0.01%	362,319 $1.71 Million
Q4 2020 Jan 22, 2021	BUY	$4.92 - $30.67 $632,200 - $3.94 Million	128,496 Added 54.95%	362,346 $1.78 Million
Q3 2020 Oct 19, 2020	BUY	$21.66 - $38.86 $2.23 Million - $4 Million	103,061 Added 78.8%	233,850 $5.63 Million
Q2 2020 Jul 23, 2020	BUY	$25.47 - $39.69 $3.33 Million - $5.19 Million	130,789 New	130,789 $5.07 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,858
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.